Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? Rationale and design for an international, open-label program to assess the effectiveness of a single pill (amlodipine/atorvastatin) to attain recommended target levels for blood pressure and lipids (The JEWEL Program)
Frederick Hobbs, G Gensini, GBJ Mancini, AJ Manolis, B Bauer, S Bohler, J Genest, R Feldman, P Harvey, TG Jenssen, M Metcalfe, M Marques da Silva
Research output: Contribution to journal › Article
22Citations
(Scopus)
Fingerprint
Dive into the research topics of 'Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? Rationale and design for an international, open-label program to assess the effectiveness of a single pill (amlodipine/atorvastatin) to attain recommended target levels for blood pressure and lipids (The JEWEL Program)'. Together they form a unique fingerprint.